Abstract
A total of 43 patients with advanced, previously untreated non-small-cell lung cancer (NSCLC) were treated with a novel nitrosourea, fotemustine, given at 100 mg/m2 on days 1 and 8. Maintenance treatment consisted of a single injection of 100 mg/m2 given every 21 days. 37 patients were evaluable for response. Of these, 5 patients had a partial response (13.5%; 95% confidence interval, 6%-28%). Toxicity comprised mainly anaemia and thrombocytopenia. Other toxicities were mild. This phase II study confirms that fotemustine is a moderately active and well-tolerated drug in NSCLC.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
MeSH terms
-
Aged
-
Anemia / chemically induced
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / pathology
-
Carcinoma, Non-Small-Cell Lung / secondary
-
Female
-
Humans
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / pathology
-
Male
-
Middle Aged
-
Nitrosourea Compounds / adverse effects
-
Nitrosourea Compounds / therapeutic use*
-
Organophosphorus Compounds / adverse effects
-
Organophosphorus Compounds / therapeutic use*
-
Quality of Life
-
Thrombocytopenia / chemically induced
Substances
-
Antineoplastic Agents
-
Nitrosourea Compounds
-
Organophosphorus Compounds
-
fotemustine